<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787304</url>
  </required_header>
  <id_info>
    <org_study_id>SHP626-201</org_study_id>
    <secondary_id>2016-000203-82</secondary_id>
    <nct_id>NCT02787304</nct_id>
  </id_info>
  <brief_title>Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the investigational treatment volixibat (SHP626)
      is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Achieving Binary Response on Liver Histology Between Volixibat (SHP626) and Placebo at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Binary response indicating (yes/no) whether a subject responded at week 48 with a reduction of at least 2 points, without worsening of fibrosis, from baseline nonalcoholic fatty Liver disease (NAFLD) activity Score (NAS). The NAS grades NAFLD on liver biopsy based on the individual scoring of steatosis, inflammation and ballooning. The NAS is assessed on a scale of 0 to 8 with higher scores indicating more severe disease and lower scores indicating less severe disease. NAS is obtained by adding steatosis(assessed on a scale of 0 to 3), inflammation (assessed on a scale of 0 to 3) and ballooning (assessed on a scale of 0 to 2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 on Liver Histology</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change in liver histology will be measured by the individual NAS components (ballooning, inflammation, steatosis). The NAS grades NAFLD on liver biopsy based on the individual scoring of steatosis, inflammation and ballooning. The NAS is assessed on a scale of 0 to 8 with higher scores indicating more severe disease and lower scores indicating less severe disease. NAS is obtained by adding steatosis (assessed on a scale of 0 to 3), inflammation (assessed on a scale of 0 to 3) and ballooning (assessed on a scale of 0 to 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 on Hepatic Steatosis</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change in hepatic steatosis will be evaluated by measuring the reduction of liver fat with magnetic resonance imaging-proton density fat-fraction (MRI-PDFF) and stratified by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 48 on liver histology</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change in liver histology will be measured by fibrosis stage. Fibrosis stage is assessed on a scale of 0-4 with higher scores indicating more severe disease and lower scores indicating less severe disease (F0= no fibrosis, F4=cirrhosis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of NASH at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Resolution of NASH is defined as total absence of ballooning [score=0], absent or mild inflammation [score 0-1], steatosis can be present [score 0-3]) without worsening of fibrosis as assessed by liver histology at Week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 48 on Serum Liver-related Biochemistry</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Serum liver-related biochemistry will be analysed by measuring alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), and total bilirubin (TB).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 on Metabolic Indicators</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Metabolic indicators will be assessed by measuring fasting serum glucose levels, insulin levels and hemoglobin A1c (HbA1c).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 on Serum Lipids</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Serum lipids level will be measured by calculating fasting total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), and triglycerides.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Non-Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>SHP626 5 Milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHP626 10 Milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHP626 20 Milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (PBO)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP626</intervention_name>
    <description>5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion</description>
    <arm_group_label>SHP626 20 Milligram (mg)</arm_group_label>
    <arm_group_label>SHP626 10 Milligram (mg)</arm_group_label>
    <arm_group_label>SHP626 5 Milligram (mg)</arm_group_label>
    <other_name>Volixibat (SHP626)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo (PBO)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. An understanding, ability, and willingness to fully comply with study procedures and
             restrictions.

          2. Ability to voluntarily provide written, signed, and dated (personally or via a legally
             authorized representative, as applicable) informed consent to participate in the
             study.

          3. Age 18-80 years inclusive. This inclusion criterion will only be assessed at the first
             screening visit.

          4. Male, or non-pregnant, non-lactating female, who is sexually active and who agrees to
             comply with the contraceptive requirements of the protocol, or females of
             non-childbearing potential. Males and females of child-bearing potential who are
             sexually active must agree to use acceptable contraception during the study and for 30
             days following the last dose of the investigational product (IP).

          5. Presence of greater than equals to (&gt;=) 5 percent (%) steatosis on screening magnetic
             resonance imaging (MRI) from a centrally read radiologist performed either during the
             screening period or within 6 months prior to the first visit.

          6. Histologic confirmation of nonalcoholic steatohepatitis (NASH) without cirrhosis
             (F0-F3) from a centrally read liver biopsy performed either during the screening
             period or within 6 months prior to the first visit with a NAS of &gt;=4 with a score of
             at least 1 in each component (steatosis, lobular inflammation, and hepatocyte
             ballooning).

        Exclusion Criteria:

          1. Presence of or history of cirrhosis or evidence of decompensated liver disease
             (example: ascites, variceal bleeding, etc.) or hepatocellular carcinoma.

          2. History or presence of other concomitant liver disease as assessed by the investigator
             or determined by laboratory findings including, but not limited to: active hepatitis B
             virus (HBV) infection (hepatitis B surface antigen [HBsAg] positive and/or hepatitis B
             virus deoxyribonucleic acid (HBVDNA) positive; subjects who are hepatitis B core
             antibody [HBcAb] positive may be eligible as long as HBsAg is negative and HBVDNA is
             non detectable), active hepatitis C virus (HCV) infection (prior exposure to HCV
             [defined as HCVAb positive] without a current or prior history of a detectable HCVRNA)
             may be eligible, alcoholic liver disease, proven autoimmune hepatitis, primary biliary
             cirrhosis (PBC), primary sclerosing cholangitis (PSC), hemochromatosis, Wilson's
             disease, alpha-1 antitrypsin deficiency, bile duct obstruction, liver primary or
             metastatic cancer.

          3. Current or recurrent disease that could affect the action, absorption, disposition, or
             laboratory assessment of the IP (including bile salt metabolism in the intestine)
             example (e.g,) uncontrolled inflammatory bowel disease, uncontrolled celiac disease,
             gastric bypass procedures (gastric lap band or gastric sleeve is acceptable), ileal or
             ileocecal resection, uncontrolled irritable bowel syndrome with predominant diarrhea,
             or history of chronic diarrhea or loose stools of any etiology.

          4. Weight change &gt;=5% after qualifying liver biopsy and/or MRI performed. If the subject
             had a liver biopsy and/or MRI within 6 months of screening, but experienced a weight
             change of &gt;=5% since the date of liver biopsy and/or MRI, the liver biopsy and/or MRI
             must be repeated at screening.

          5. Contraindications to MRI (e.g, claustrophobia, coronary stents, coronary implantable
             devices, girth, etc.). Stents or other devices may be allowed, at the investigator's
             discretion, if they do not interfere with the functioning of the MRI machine.

          6. Current or relevant history of physical or psychiatric illness, any medical disorder
             that may require treatment or make the subject unlikely to complete the study.

          7. Treatment with Vitamin E, thiazolidinediones (TZD), or glucagon-like peptide-1
             receptor agonists (GLP-1 RA) unless subject on a stable dose for 6 months prior to
             qualifying liver biopsy and not initiated after qualifying liver biopsy and will
             continue the same dosing regimen throughout study participation.

          8. Uncontrolled diabetes defined as HbA1c of &gt;=9.5% within 60 days prior to enrollment.

          9. Current use of any medication (including over-the-counter, herbal, or homeopathic
             preparations) that could affect the action, absorption, or disposition of the IP, or
             clinical or laboratory assessment. (Current use is defined as use within 14 days of
             screening). Subjects currently taking insulin will not be excluded; however, they must
             be on a stable dose for at least 30 days prior to screening, or a sliding scale of
             insulin is allowed as long as the subject's HbA1c remains less than (&lt;) 9.5%.

         10. Use of drugs, herbs or supplements historically associated with causing or worsening
             NAFLD/NASH for less than 6 months prior to liver biopsy, or initiated any time after
             liver biopsy performed, including the use of total parenteral nutrition (TPN).

         11. Serum aspartate aminotransferase (AST) greater than (&gt;) 7 times upper limit of normal
             (ULN) at screening.

         12. Serum alanine aminotransferase (ALT) &gt;7 times ULN at screening.

         13. Elevated serum creatinine &gt;=2.0 milligram/deciliter (mg/dL).

         14. International normalized ratio (INR) &gt;1.3

         15. Total bilirubin (TB) &gt;2.0 times ULN at screening (Except for documented Gilbert's
             syndrome with bilirubin levels 20 micromole per liter (mcmol/L) to 90 mcmol/L (1.2 to
             5.3 mg/dL) and with a ratio of unconjugated/conjugated bilirubin that is
             commensurately higher).

         16. Platelet count &lt;130 Ã— 10^9/liter (L)

         17. Medical history of impaired hemostasis or use of anticoagulant medication (use of
             antiplatelet medications, such as low-dose, that is 81 mg, aspirin [ASA] or
             clopidogrel [Plavix] will be allowed).

         18. Uncontrolled thyroid disease.

         19. Type 1 diabetes mellitus.

         20. Known or suspected intolerance or hypersensitivity to the IP, closely-related
             compounds, or any of the stated ingredients.

         21. Known history of alcohol or other substance abuse within the last year or at any time
             during the study based on investigator's discretion. Weekly alcohol intake greater
             than 21 grams/day for males and 14 grams/day for females on average or inability to
             reliably quantify alcohol consumption based on investigator's judgment.

         22. Within 6 months of MRI and liver biopsy:

               -  Have used any IP.

               -  Have been enrolled in a clinical study (including vaccine studies) that, in the
                  investigator's opinion, may impact this Shire-sponsored study.

         23. Inability to safely obtain a liver biopsy.

         24. Females who are pregnant, planning to become pregnant, or are breastfeeding, or males
             who are planning to father a child during study participation.

         25. The anticipated need for a surgical procedure during the study that could interfere
             with the treatment.

         26. Known positivity for human immunodeficiency virus (HIV) infection.

         27. Cancer within 5 years of screening, except for basal or squamous cell carcinoma of the
             skin or in situ cervical carcinoma that has been treated with no evidence of
             recurrence.

         28. History of noncompliance with medical regimens, unreliability, mental instability or
             incompetence that could compromise the validity of informed consent or lead to
             noncompliance with the study protocol.

         29. Any other conditions or abnormalities which, in the opinion of the investigator, may
             compromise the safety of the subject, or interfere with the subject participating.

         30. Subject is currently enrolled in this study at any study site (unless the subject is
             transferring to another qualified study site with prior sponsor approval).

         31. Subjects who are employees at the unit of the investigational site that is conducting
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Call Contact</last_name>
    <phone>1 866-842-5335</phone>
    <email>clinicaltransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Hassanein</last_name>
      <phone>619-522-0330</phone>
      <email>thassanein@livercenters.com</email>
    </contact>
    <investigator>
      <last_name>Tarek Hassanein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fresno Clinical Research Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Sheikh</last_name>
      <phone>559-970-3441</phone>
      <email>liverdisease@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Muhammad Sheikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ceders-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mazen Noureddin, MD</last_name>
      <phone>310-423-7088</phone>
      <email>mazen.noureddin@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Mazen Noureddin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Liver Research Institute</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Mena, MD</last_name>
      <phone>626-440-7325</phone>
    </contact>
    <investigator>
      <last_name>Edward Mena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeid Kayali</last_name>
      <phone>909-883-2999</phone>
      <email>zkayali@ieliverfoundation.com</email>
    </contact>
    <investigator>
      <last_name>Zeid Kayali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Denver Gastroenterology, PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Kugelmas</last_name>
      <phone>303-406-4139</phone>
      <email>kugelmas@gutfeelings.com</email>
    </contact>
    <investigator>
      <last_name>Marcelo Kugelmas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medstar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amol Rangnekar, Dr</last_name>
      <phone>202-444-3700</phone>
      <email>amol.s.rangnekar@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Amol Rangnekar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>George Washington (GW) Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Latham</last_name>
      <phone>202-994-5057</phone>
      <email>platham@mfa.gwu.edu</email>
    </contact>
    <investigator>
      <last_name>Patricia Latham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Schiff</last_name>
      <phone>305-243-4615</phone>
      <email>eschiff@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Eugene Schiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida Center of Gastroenterology</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Davis</last_name>
      <phone>561-798-2425</phone>
      <email>mdavis@digestivecareonline.com</email>
    </contact>
    <investigator>
      <last_name>Mitchell Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Associates of Wellstar Atlanta Medical</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Pearlman</last_name>
    </contact>
    <investigator>
      <last_name>Brian Pearlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miriam Vos</last_name>
      <phone>404-785-1281</phone>
      <email>mvos@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Miriam Vos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aasim Sheikh, Dr</last_name>
      <phone>679-819-4217</phone>
      <email>asheikh@gigeorgia.com</email>
    </contact>
    <investigator>
      <last_name>Aasim Sheikh, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Queen's Medical Center - Liver Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Naoky Tsai</last_name>
    </contact>
    <investigator>
      <last_name>Naoky Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Sanchez</last_name>
      <phone>319-384-7283</phone>
      <email>Antonio-sanchez@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Antonio Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liver Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Smart</last_name>
      <phone>502-852-6991</phone>
      <email>Laura.Smart@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Smart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredric Regenstein</last_name>
      <phone>504-988-1619</phone>
      <email>fregens@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Fredric Regenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Center, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Dies</last_name>
      <phone>318-631-9121</phone>
      <email>dfdies@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>David Dies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Thuluvath, MD</last_name>
      <phone>410-332-9356</phone>
    </contact>
    <investigator>
      <last_name>Paul Thuluvath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natarajan Ravendhran, MD</last_name>
      <phone>410-737-0053</phone>
      <email>n.ravendhran@ddamd.com</email>
    </contact>
    <investigator>
      <last_name>Natarajan Ravendhran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Lai</last_name>
      <phone>617-632-1094</phone>
      <email>mlai@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Michelle Lai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyongyi Szabo</last_name>
      <phone>508-856-6113</phone>
      <email>Gyongyi.Szabo@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Gyongyi Szabo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Gordon, MD</last_name>
      <phone>313-916-9465</phone>
      <email>sgordon3@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Stuart Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Borg, MD</last_name>
      <phone>601-984-4540</phone>
      <email>bborg@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Borg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Freilich</last_name>
      <phone>816-759-5274</phone>
      <email>brad@kcgastro.com</email>
    </contact>
    <investigator>
      <last_name>Bradley Freilich, Freilich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arifa Toor</last_name>
      <phone>603-650-5261</phone>
      <email>Arifa.Toor@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Arifa Toor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health Inc.</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bernstein</last_name>
      <phone>516-562-4664</phone>
      <email>dbernste@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>David Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Concorde Medical Group PLLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hillel Tobias</last_name>
      <phone>212-889-5544</phone>
      <email>docstobias@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hillel Tobias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Huang</last_name>
      <phone>585-275-4711</phone>
      <email>jonathan_huang@urmc.rochester.ed</email>
    </contact>
    <investigator>
      <last_name>Jonathan Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Liver Disease</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew deLemos</last_name>
      <phone>704-355-6649</phone>
      <email>Andrew.delemos@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Andrew deLemos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DUMC-Gastroenterology</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manal Abdelmalek</last_name>
      <phone>919-684-3262</phone>
      <email>manal.abdelmalek@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Manal Abdelmalek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Poulos</last_name>
      <phone>910-484-8163</phone>
      <email>Cumberland@cumberlandresearchassociates.com</email>
    </contact>
    <investigator>
      <last_name>John Poulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Center for Liver Disease</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Reindollar</last_name>
      <phone>704-978-0044</phone>
      <email>robert.reindollar@piedmonthealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Robert Reindollar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaideep Behari</last_name>
      <phone>412-647-4932</phone>
      <email>behajx@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jaideep Behari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Don Rockey</last_name>
      <phone>843-792-2914</phone>
      <email>rockey@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Don Rockey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinsearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Krause</last_name>
      <phone>423-698-4584</phone>
      <email>rkrause@clinsearch-us.com</email>
    </contact>
    <investigator>
      <last_name>Richard Krause, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of TN Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>038104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjaya Satapathy</last_name>
      <phone>901-516-6014</phone>
      <email>ssatapat@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Sanjaya Satapathy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Herring Jr.</last_name>
    </contact>
    <investigator>
      <last_name>Robert Herring Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Center for Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imtiaz Alam, MD</last_name>
    </contact>
    <investigator>
      <last_name>Imtiaz Alam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Health Systems Clinical</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adil Habib</last_name>
      <phone>214-947-4450</phone>
      <email>AdilHabib@mhd.com</email>
    </contact>
    <investigator>
      <last_name>Adil Habib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Advanced Liver Therapies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John M Vierling</last_name>
      <phone>713-798-1966</phone>
      <email>vierling@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>John M Vierling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamir Miloh</last_name>
      <phone>832-822-2778</phone>
      <email>tamir.miloh@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Tamir Miloh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DHAT Research Institute</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75082</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Sarles</last_name>
      <phone>972-487-1436</phone>
      <email>harry.sarles@dhat.com</email>
    </contact>
    <investigator>
      <last_name>Harry Sarles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UVM Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Lidofsky</last_name>
      <phone>802-847-2554</phone>
      <email>steven.lidofsky@uvm.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Lidofsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Smith</last_name>
      <phone>757-466-0165</phone>
      <email>jhsresearch@dlds.org</email>
    </contact>
    <investigator>
      <last_name>John Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mitchell Shiffman</last_name>
      <phone>804-977-8920</phone>
      <email>Mitchell_shiffman@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell Shiffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arun Sanyal</last_name>
      <phone>804-828-4060</phone>
      <email>arun.sanyal@cvuheath.org</email>
    </contact>
    <investigator>
      <last_name>Arun Sanyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blaire Burman</last_name>
      <phone>206-223-2319</phone>
      <email>blaire.burman@virginiamason.org</email>
    </contact>
    <investigator>
      <last_name>Blaire Burman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UW Digestive Health Center (DHC)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adnan Said</last_name>
      <phone>608-263-4034</phone>
      <email>axs@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Adnan Said, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary Liver Unit</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Eksteen, MD</last_name>
      <phone>1-403-220-3719</phone>
      <email>B.eksteen@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Johannes Eksteen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LAIR Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Tam, MD</last_name>
      <phone>604-876-5122</phone>
      <email>etam@laircentre.com</email>
    </contact>
    <investigator>
      <last_name>Edward Tam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver ID Research and Care Centre Society</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Conway</last_name>
      <phone>604-642-6429</phone>
      <email>brian.conway@vidc.ca</email>
    </contact>
    <investigator>
      <last_name>Brian Conway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Heath Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3HJ 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus McLeod</last_name>
      <phone>919-684-3262</phone>
      <email>magnus.mcleod@nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Magnus McLeod, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdy Elkhashab</last_name>
      <phone>416-652-2512</phone>
      <email>melkashabmd@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Magdy Elkhashab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRCHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne-Marie Giard</last_name>
      <phone>514-890-8000</phone>
      <email>Jeannemariegiard@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jeanne-Marie Giard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPR: Medical Sciences Campus</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose E Rivera</last_name>
      <phone>787-754-0101</phone>
      <email>jose.rivera120@upr.edu</email>
    </contact>
    <investigator>
      <last_name>Jose E Rivera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>West Midlands</city>
        <state>Birmingham</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Newsome</last_name>
      <phone>44-1214-721311</phone>
      <email>P.N.Newsome@bham.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Philip Newsome, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS Tayside</name>
      <address>
        <city>Taysdie</city>
        <state>Dundee City</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Dillon</last_name>
      <phone>44-1382-632334</phone>
      <email>j.f.dillon@dundee.ac.uk</email>
    </contact>
    <investigator>
      <last_name>John Dillon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>Hampstead</city>
        <state>London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanouil</last_name>
      <phone>44-20-7794-0500</phone>
      <email>emmanouil.tsochatzis@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Emmanouil Tsochatzis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norfolk &amp; Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arun Shankar</last_name>
      <phone>01603 288234</phone>
      <email>arun.shankar@nnuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Arun Shankar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Cobbold</last_name>
      <phone>44-01865-228756</phone>
      <email>Jeremy.Cobbold@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jeremy Cobbold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Alazawi, MD</last_name>
      <phone>44-020-3594-6773</phone>
      <email>w.alazawi@qmul.ac.uk</email>
    </contact>
    <investigator>
      <last_name>William Alazawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham Digestive Diseases Centre and Biomedical Research Unit</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guruprasad Aithal</last_name>
      <phone>44-0115-9249924 70441</phone>
      <email>guru.aithal@nuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Guruprasad Aithal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abertawe Bro Morgannwg University</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chin Ch'ng</last_name>
      <phone>44-792-285809</phone>
      <email>chinlye.chng@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chin Ch'ng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>York Clinical Research Facility</name>
      <address>
        <city>York</city>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Millson, MD</last_name>
      <phone>44-01904-721893</phone>
      <email>Charles.Millson@york.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Charles Millson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.theviastudy.com/</url>
    <description>For More Information on The VIA Study</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NAFLD activity score</keyword>
  <keyword>ASBTi</keyword>
  <keyword>MRI PDFF</keyword>
  <keyword>NAS</keyword>
  <keyword>NAFLD</keyword>
  <keyword>liver disease</keyword>
  <keyword>ASBT</keyword>
  <keyword>MRI proton density fat fraction</keyword>
  <keyword>nonalcoholic steatohepatitis</keyword>
  <keyword>apical sodium dependent bile acid transporter inhibitor</keyword>
  <keyword>fatty liver</keyword>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Acids and Salts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

